Recursion Pharmaceuticals, Inc. RXRX Business Segments — Salaries
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LaborAndRelatedExpense.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s business segments — salaries.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s business segments — salaries?
- Recursion Pharmaceuticals, Inc. (RXRX) reported business segments — salaries of $74.3M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s business segments — salaries changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s business segments — salaries decreased by 11.1% year-over-year, from $83.55M to $74.3M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s business segments — salaries?
- Over 3 years (2022 to 2025), Recursion Pharmaceuticals, Inc.'s business segments — salaries has grown at a 29.5% compound annual growth rate (CAGR), from $139.67M to $303.48M.
- What does business segments — salaries mean?
- Captures the total compensation expenses, including wages and benefits, allocated to personnel within the reportable business segment. Monitoring this metric helps assess the human capital investment required to sustain operations and drive research and development initiatives.